Search

Your search keyword '"Nasri, Flora"' showing total 188 results
Start Over Author "Nasri, Flora"
188 results on '"Nasri, Flora"'

6. Ketamine for psychotic depression: An overview of the glutamatergic system and ketamine's mechanisms associated with antidepressant and psychotomimetic effects

Author

Le, Tuyen T., Di Vincenzo, Joshua D., Teopiz, Kayla M., Lee, Yena, Cha, Danielle S., Lui, Leanna M.W., Rodrigues, Nelson B., Ho, Roger C., Cao, Bing, Lin, Kangguang, Nasri, Flora, Gill, Hartej, Lipsitz, Orly, Subramaniapillai, Mehala, Mansur, Rodrigo B., Rosenblat, Joshua D., and McIntyre, Roger S.

Published
2021
Full Text
View/download PDF

7. The effect of intravenous ketamine on cognitive functions in adults with treatment-resistant major depressive or bipolar disorders: Results from the Canadian rapid treatment center of excellence (CRTCE)

Author

McIntyre, Roger S., Rosenblat, Joshua D., Rodrigues, Nelson B., Lipsitz, Orly, Chen-Li, David, Lee, Jung Goo, Nasri, Flora, Subramaniapillai, Mehala, Kratiuk, Kevin, Wang, Andrew, Gill, Hartej, Mansur, Rodrigo B., Ho, Roger, Lin, Kangguang, and Lee, Yena

Published
2021
Full Text
View/download PDF

13. Early symptomatic improvements as a predictor of response to repeated-dose intravenous ketamine: Results from the Canadian Rapid Treatment Center of Excellence

Author

Lipsitz, Orly, McIntyre, Roger S., Rodrigues, Nelson B., Kaster, Tyler S., Cha, Danielle S., Brietzke, Elisa, Gill, Hartej, Nasri, Flora, Lin, Kangguang, Subramaniapillai, Mehala, Kratiuk, Kevin, Teopiz, Kayla, Lui, Leanna M.W., Lee, Yena, Ho, Roger, Shekotikhina, Margarita, Mansur, Rodrigo B., and Rosenblat, Joshua D.

Published
2021
Full Text
View/download PDF

17. The Meaningful Change Threshold as Measured by the 16-Item Quick Inventory of Depressive Symptomatology in Adults with Treatment-Resistant Major Depressive and Bipolar Disorder Receiving Intravenous Ketamine

Author

McIntyre, Roger S., Lipsitz, Orly, Lui, Leanna M.W., Rodrigues, Nelson B., Gill, Hartej, Nasri, Flora, Ling, Rui, Teopiz, Kayla M., Ho, Roger C., Subramaniapillai, Mehala, Kratiuk, Kevin, Mansur, Rodrigo B., Jones, Brett D.M., Lee, Yena, and Rosenblat, Joshua D.

Published
2021
Full Text
View/download PDF

19. Exploring brain insulin resistance in adults with bipolar depression using extracellular vesicles of neuronal origin

Author

Mansur, Rodrigo B., Delgado-Peraza, Francheska, Subramaniapillai, Mehala, Lee, Yena, Iacobucci, Michelle, Nasri, Flora, Rodrigues, Nelson, Rosenblat, Joshua D., Brietzke, Elisa, Cosgrove, Victoria E., Kramer, Nicole E., Suppes, Trisha, Raison, Charles L., Fagiolini, Andrea, Rasgon, Natalie, Chawla, Sahil, Nogueras-Ortiz, Carlos, Kapogiannis, Dimitrios, and McIntyre, Roger S.

Published
2021
Full Text
View/download PDF

23. The effect of intravenous, intranasal, and oral ketamine in mood disorders: A meta-analysis

Author

McIntyre, Roger S., Carvalho, Isabelle P., Lui, Leanna M.W., Majeed, Amna, Masand, Prakash S., Gill, Hartej, Rodrigues, Nelson B., Lipsitz, Orly, Coles, Alexandria C., Lee, Yena, Tamura, Jocelyn K., Iacobucci, Michelle, Phan, Lee, Nasri, Flora, Singhal, Nikhita, Wong, Elizabeth R., Subramaniapillai, Mehala, Mansur, Rodrigo, Ho, Roger, Lam, Raymond W., and Rosenblat, Joshua D.

Published
2020
Full Text
View/download PDF

26. The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence

Author

McIntyre, Roger S, Rodrigues, Nelson B, Lee, Yena, Lipsitz, Orly, Subramaniapillai, Mehala, Gill, Hartej, Nasri, Flora, Majeed, Amna, Lui, Leanna M W, Senyk, Olena, Phan, Lee, Carvalho, Isabelle P., Siegel, Ashley, Mansur, Rodrigo B., Brietzke, Elisa, Kratiuk, Kevin, Arekapudi, Anil K., Abrishami, Amir, Chau, Edmond H., Szpejda, Witold, and Rosenblat, Joshua D.

Published
2020
Full Text
View/download PDF

29. An App-Based Digit Symbol Substitution Test for Assessment of Cognitive Deficits in Adults With Major Depressive Disorder: Evaluation Study

Author

McIntyre, Roger S, primary, Lipsitz, Orly, additional, Rodrigues, Nelson B, additional, Subramaniapillai, Mehala, additional, Nasri, Flora, additional, Lee, Yena, additional, Fehnert, Ben, additional, King, James, additional, Chrones, Lambros, additional, Kratiuk, Kevin, additional, Uddin, Sharif, additional, Rosenblat, Joshua D, additional, Mansur, Rodrigo B, additional, and McCue, Maggie, additional

Published
2022
Full Text
View/download PDF

30. Ketamine as potential treatment for postpartum depression:A narrative review

Author

Chen-Li, David, Lui, Leanna M.W., Rosenblat, Joshua D., Lipsitz, Orly, Teopiz, Kayla M., Ho, Roger, Vinberg, Maj, Golts, Marina, Jawad, Muhammad Youshay, Lee, Yena, Nasri, Flora, Gill, Hartej, McIntyre, Roger S., Chen-Li, David, Lui, Leanna M.W., Rosenblat, Joshua D., Lipsitz, Orly, Teopiz, Kayla M., Ho, Roger, Vinberg, Maj, Golts, Marina, Jawad, Muhammad Youshay, Lee, Yena, Nasri, Flora, Gill, Hartej, and McIntyre, Roger S.

Abstract

BACKGROUND: Postpartum depression (PPD) is a severe, debilitating mood disorder with consequences for both mothers and children, highlighting the need for rapid-acting and effective treatments for PPD. The aim of this narrative review is to synthesize the available literature on the administration of ketamine for PPD and propose ketamine as a viable and advantageous treatment. METHODS: A search was conducted on MEDLINE/PubMed, PsycInfo, and Embase databases from inception to October 10, 2021 for preclinical studies, interventional studies (ie, open-label and randomized controlled trials), as well as systematic reviews and meta-analyses evaluating the use of ketamine in postpartum populations. Completed and ongoing clinical trials were identified on ClinicalTrials.gov. RESULTS: Four clinical trials were identified. Results from this review support additional investigation into ketamine as a potential treatment for PPD. CONCLUSIONS: Ketamine may be a favorable option for treating PPD due to its antidepressive and analgesic effects, short infusion time, and rapid clearance from the maternal bloodstream. However, there is insufficient evidence to support its use in this population, underscoring the importance of additional clinical research investigating ketamine for PPD.

Published
2022

31. The effect of ketamine on anhedonia:improvements in dimensions of anticipatory, consummatory, and motivation-related reward deficits

Author

Nogo, Danica, Jasrai, Ashitija K., Kim, Haeun, Nasri, Flora, Ceban, Felicia, Lui, Leanna M.W., Rosenblat, Joshua D., Vinberg, Maj, Ho, Roger, McIntyre, Roger S., Nogo, Danica, Jasrai, Ashitija K., Kim, Haeun, Nasri, Flora, Ceban, Felicia, Lui, Leanna M.W., Rosenblat, Joshua D., Vinberg, Maj, Ho, Roger, and McIntyre, Roger S.

Abstract

Anhedonia is a common, persistent, and disabling condition. However, available therapeutics primarily focus on the reduction of depressive and negative symptoms rather than amelioration of deficits in positive affect. As such, extant drug treatments remain largely ineffective in treating symptoms of anhedonia. Ketamine is a rapid-acting and novel therapeutic treatment for treatment-resistant depression, which has also been demonstrated to attenuate symptoms of anhedonia. However, the literature on the anti-anhedonic effects of ketamine is limited—especially within independent dimensions of this symptom domain. Herein, this review examined the impact of ketamine treatment on anhedonia and its dimensions on anticipatory, consummatory, and motivation-related reward deficits. Overall, the findings have shown a trend towards symptom reduction and/or improvements in anhedonia and their respective subdomains, in both human and preclinical studies, as well as its potential to provide additional benefit in reducing suicidality and improving quality-of-life. Although further research is required in understanding the long-term efficacy and mechanism, ketamine may provide an effective and rapid-acting therapeutic in an otherwise unmet domain.

Published
2022

32. Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellence

Author

Rodrigues, Nelson B., McIntyre, Roger S., Lipsitz, Orly, Lee, Yena, S., Danielle, Nasri, Flora, Gill, Hartej, Lui, Leanna M.W., Subramaniapillai, Mehala, Kratiuk, Kevin, Lin, Kangguang, Ho, Roger, Mansur, Rodrigo B., and Rosenblat, Joshua D.

Abstract

Rigorous clinical trials suggest ketamine is safe and well-tolerated in patients with treatment-resistant depression (TRD). There is a paucity of data on the safety and tolerability of ketamine in community-based clinics treating patients with TRD. Retrospective data was analyzed from 203 patients with TRD who received repeat-dose IV ketamine. Safety was operationalized as hemodynamic changes. Tolerability was evaluated through the reporting of adverse events and dissociation symptom severity, as measured by the Clinician-Administered Dissociative States Scale. Ketamine was well-tolerated, with less than 5% of patients withdrawing due to tolerability concerns. Blood pressure significantly increased during infusion, with 44.3% meeting criteria for treatment-emergent hypertension (i.e., blood pressure ≥ 165/100 mmHg). 12% of patients exhibiting hypertension required pharmacological intervention. The most frequently reported adverse events included drowsiness (56.4%), dizziness (45.2%), dissociation (35.6%), and nausea (13.3%). Dissociation severity significantly attenuated after the first infusion, but plateaued for subsequent infusions. Intravenous ketamine was safe and well-tolerated. Hypertension was commonly observed and was often transient. Dissociation was most frequently reported after the first infusion but remained a consistent but not treatment-limiting adverse event thereafter. No patients exhibited psychosis, mania, or new onset suicidality with IV ketamine.

Published
2022
Full Text
View/download PDF

33. Efficacy of ketamine and esketamine on functional outcomes in treatment-resistant depression: A systematic review

Author

Ng, Jason, primary, Rosenblat, Joshua D., additional, Lui, Leanna M.W., additional, Teopiz, Kayla M., additional, Lee, Yena, additional, Lipsitz, Orly, additional, Mansur, Rodrigo B., additional, Rodrigues, Nelson B., additional, Nasri, Flora, additional, Gill, Hartej, additional, Cha, Danielle S., additional, Subramaniapillai, Mehala, additional, Ho, Roger C., additional, Cao, Bing, additional, and McIntyre, Roger S., additional

Published
2021
Full Text
View/download PDF

34. Association Between Mood Disorders and Risk of COVID-19 Infection, Hospitalization, and Death

Author

Ceban, Felicia, primary, Nogo, Danica, additional, Carvalho, Isidro P., additional, Lee, Yena, additional, Nasri, Flora, additional, Xiong, Jiaqi, additional, Lui, Leanna M. W., additional, Subramaniapillai, Mehala, additional, Gill, Hartej, additional, Liu, Rene N., additional, Joseph, Prianca, additional, Teopiz, Kayla M., additional, Cao, Bing, additional, Mansur, Rodrigo B., additional, Lin, Kangguang, additional, Rosenblat, Joshua D., additional, Ho, Roger C., additional, and McIntyre, Roger S., additional

Published
2021
Full Text
View/download PDF

35. Repetitive transcranial magnetic stimulation for cognitive function in adults with bipolar disorder: A pilot study

Author

McIntyre, Roger S., primary, Lee, Yena, additional, Rodrigues, Nelson B., additional, Nasri, Flora, additional, Lao, Guohui, additional, Zeng, Wan, additional, Ye, Biru, additional, Li, Ripeng, additional, Rosenblat, Joshua D., additional, Mansur, Rodrigo B., additional, Subramaniapillai, Mehala, additional, Lui, Leanna M.W., additional, Teopiz, Kayla M., additional, Liu, Tao, additional, Xiong, Jiaqi, additional, Zhang, Ruoxi, additional, Lu, Weicong, additional, Xu, Guiyun, additional, Huang, Xiong, additional, and Lin, Kangguang, additional

Published
2021
Full Text
View/download PDF

36. Suicide reduction in Canada during the COVID-19 pandemic: lessons informing national prevention strategies for suicide reduction

Author

McIntyre, Roger S, primary, Lui, Leanna MW, additional, Rosenblat, Joshua D, additional, Ho, Roger, additional, Gill, Hartej, additional, Mansur, Rodrigo B, additional, Teopiz, Kayla, additional, Liao, Yuhua, additional, Lu, Ciyong, additional, Subramaniapillai, Mehala, additional, Nasri, Flora, additional, and Lee, Yena, additional

Published
2021
Full Text
View/download PDF

37. Does pre-treatment functioning influence response to intravenous ketamine in adults with treatment-resistant depression?

Author

McIntyre, Roger S, primary, Lipsitz, Orly, additional, Lui, Leanna M W, additional, Rodrigues, Nelson B, additional, Lee, Yena, additional, Ho, Roger C, additional, Subramaniapillai, Mehala, additional, Gill, Hartej, additional, Cha, Danielle S, additional, Lin, Kangguang, additional, Teopiz, Kayla M, additional, Nasri, Flora, additional, Mansur, Rodrigo B, additional, Kratiuk, Kevin, additional, and Rosenblat, Joshua D, additional

Published
2021
Full Text
View/download PDF

38. Government response moderates the mental health impact of COVID-19: A systematic review and meta-analysis of depression outcomes across countries

Author

Lee, Yena, primary, Lui, Leanna M.W., additional, Chen-Li, David, additional, Liao, Yuhua, additional, Mansur, Rodrigo B., additional, Brietzke, Elisa, additional, Rosenblat, Joshua D., additional, Ho, Roger, additional, Rodrigues, Nelson B., additional, Lipsitz, Orly, additional, Nasri, Flora, additional, Cao, Bing, additional, Subramaniapillai, Mehala, additional, Gill, Hartej, additional, Lu, Ciyong, additional, and McIntyre, Roger S., additional

Published
2021
Full Text
View/download PDF

39. sj-pdf-1-jrs-10.1177_01410768211043186 - Supplemental material for Suicide reduction in Canada during the COVID-19 pandemic: lessons informing national prevention strategies for suicide reduction

Author

McIntyre, Roger S, Lui, Leanna MW, Rosenblat, Joshua D, Ho, Roger, Gill, Hartej, Mansur, Rodrigo B, Teopiz, Kayla, Liao, Yuhua, Lu, Ciyong, Subramaniapillai, Mehala, Nasri, Flora, and Lee, Yena

Subjects
Medicine
Abstract

Supplemental material, sj-pdf-1-jrs-10.1177_01410768211043186 for Suicide reduction in Canada during the COVID-19 pandemic: lessons informing national prevention strategies for suicide reduction by Roger S McIntyre, Leanna MW Lui, Joshua D Rosenblat, Roger Ho, Hartej Gill, Rodrigo B Mansur, Kayla Teopiz, Yuhua Liao, Ciyong Lu, Mehala Subramaniapillai, Flora Nasri and Yena Lee in Journal of the Royal Society of Medicine

Published
2021
Full Text
View/download PDF

41. Impact of SARS-CoV-2 Infection on Cognitive Function: A Systematic Review

Author

Alnefeesi, Yazen, primary, Siegel, Ashley, additional, Lui, Leanna M. W., additional, Teopiz, Kayla M., additional, Ho, Roger C. M., additional, Lee, Yena, additional, Nasri, Flora, additional, Gill, Hartej, additional, Lin, Kangguang, additional, Cao, Bing, additional, Rosenblat, Joshua D., additional, and McIntyre, Roger S., additional

Published
2021
Full Text
View/download PDF

42. The effectiveness of ketamine on anxiety, irritability, and agitation:Implications for treating mixed features in adults with major depressive or bipolar disorder

Author

McIntyre, Roger S., Lipsitz, Orly, Rodrigues, Nelson B., Lee, Yena, Cha, Danielle S., Vinberg, Maj, Lin, Kangguang, Malhi, Gin S., Subramaniapillai, Mehala, Kratiuk, Kevin, Fagiolini, Andrea, Gill, Hartej, Nasri, Flora, Mansur, Rodrigo B., Suppes, Trisha, Ho, Roger, Rosenblat, Joshua D., McIntyre, Roger S., Lipsitz, Orly, Rodrigues, Nelson B., Lee, Yena, Cha, Danielle S., Vinberg, Maj, Lin, Kangguang, Malhi, Gin S., Subramaniapillai, Mehala, Kratiuk, Kevin, Fagiolini, Andrea, Gill, Hartej, Nasri, Flora, Mansur, Rodrigo B., Suppes, Trisha, Ho, Roger, and Rosenblat, Joshua D.

Abstract

Objective: To determine the effectiveness of intravenous (IV) ketamine on anxiety, irritability, agitation, and suicidality, in adults with treatment-resistant major depressive disorder (MDD) or bipolar disorder (BD). Method: Adults (N = 201) with treatment-resistant MDD or BD received repeat-dose IV ketamine treatment at a community-based clinic. Mixed features were measured using symptoms of anxiety, irritability, and agitation (AIA), as measured by the Generalized Anxiety Disorder-7 (GAD-7) scale. The Quick Inventory for Depressive Symptomatology Self-Report-16 (QIDS-SR16) was used to measure overall treatment response, and the QIDS-SR16 suicidal ideation (SI) item was used to measure change in SI symptoms with ketamine treatment. The anxiety, irritability, and agitation items on the GAD-7 were used to assess effectiveness of IV ketamine in treating symptoms of mixed features. Results: In this retrospective analysis, 113 participants met AIA criteria. Participants with AIA experienced a significantly greater reduction in overall depressive symptoms (F(1, 558) = 9.49, P =.002), SI (F(1, 558) = 3.103, P =.079), anxiety (F(1, 198) = 5.52, P =.007), irritability (F(1, 198) = 28.35, P <.001), and agitation as measured by “trouble relaxing” (F(1, 198) = 6.70, P =.010) from baseline compared to the non-AIA group, regardless of number of treatments received. Conclusions: Our preliminary results suggest that IV ketamine is effective in rapidly treating AIA and SI in adults with treatment-resistant mood disorders. This observation suggests that IV ketamine could be considered a treatment alternative for adults with MDD or BD presenting with mixed features.

Published
2020

43. Management of cognitive impairment in bipolar disorder: a systematic review of randomized controlled trials

Author

Tamura, Jocelyn K., primary, Carvalho, Isabelle P., additional, Leanna, Lui M. W., additional, Feng, Jia Nuo, additional, Rosenblat, Joshua D., additional, Mansur, Rodrigo, additional, Lee, Yena, additional, Cha, Danielle S., additional, Teopiz, Kayla, additional, Ahmad, Zara, additional, Nasri, Flora, additional, Kim, Jiin, additional, and McIntyre, Roger S., additional

Published
2021
Full Text
View/download PDF

44. Effectiveness of intravenous ketamine in mood disorder patients with a history of neurostimulation

Author

Rodrigues, Nelson B., primary, Siegel, Ashley, additional, Lipsitz, Orly, additional, Cha, Danielle S., additional, Gill, Hartej, additional, Nasri, Flora, additional, Simonson, Kevin, additional, Shekotikhina, Margarita, additional, Lee, Yena, additional, Subramaniapillai, Mehala, additional, Kratiuk, Kevin, additional, Lin, Kangguang, additional, Ho, Roger, additional, Mansur, Rodrigo B., additional, McIntyre, Roger S., additional, and Rosenblat, Joshua D., additional

Published
2020
Full Text
View/download PDF

45. Does body mass index predict response to intravenous ketamine treatment in adults with major depressive and bipolar disorder? Results from the Canadian Rapid Treatment Center of Excellence

Author

Lipsitz, Orly, primary, McIntyre, Roger S., additional, Rodrigues, Nelson B., additional, Lee, Yena, additional, Gill, Hartej, additional, Subramaniapillai, Mehala, additional, Kratiuk, Kevin, additional, Nasri, Flora, additional, Mansur, Rodrigo B., additional, and Rosenblat, Joshua D., additional

Published
2020
Full Text
View/download PDF

46. Management of cognitive impairment in bipolar disorder: a systematic review of randomized controlled trials

Author

Tamura, Jocelyn K., Carvalho, Isabelle P., Leanna, Lui M. W., Feng, Jia Nuo, Rosenblat, Joshua D., Mansur, Rodrigo, Lee, Yena, Cha, Danielle S., Teopiz, Kayla, Ahmad, Zara, Nasri, Flora, Kim, Jiin, and McIntyre, Roger S.

Abstract

AbstractCognitive impairment is common in bipolar disorder and is emerging as a therapeutic target to enhance quality of life and function. A systematic search was conducted on PubMed, PsycInfo, Cochrane, clinicaltrials.gov, and Embase databases for blinded or open-label randomized controlled trials evaluating the pro-cognitive effects of pharmacological, neurostimulation, or psychological interventions for bipolar disorder. Twenty-two trials were identified, evaluating a total of 16 different pro-cognitive interventions. The methodological quality of the identified trials were assessed using the Cochrane Risk of Bias tool. Currently, no intervention (i.e., pharmacologic, neurostimulation, cognitive remediation) has demonstrated robust and independent pro-cognitive effects in adults with bipolar disorder. Findings are preliminary and methodological limitations limit the interpretation of results. Methodological considerations including, but not limited to, the enrichment with populations with pre-treatment cognitive impairment, as well as the inclusion of individuals who are in remission are encouraged. Future trials may also consider targeting interventions to specific cognitive subgroups and the use of biomarkers of cognitive function.

Published
2022
Full Text
View/download PDF

47. The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of Excellence

Author

McIntyre, Roger S, primary, Rodrigues, Nelson B, additional, Lipsitz, Orly, additional, Nasri, Flora, additional, Gill, Hartej, additional, Lui, Leanna MW, additional, Subramaniapillai, Mehala, additional, Kratiuk, Kevin, additional, Teopiz, Kayla, additional, Ho, Roger, additional, Lee, Yena, additional, Mansur, Rodrigo B, additional, and Rosenblat, Joshua D, additional

Published
2020
Full Text
View/download PDF

48. Antidepressant Medications and Weight Change: A Narrative Review

Author

Gill, Hartej, primary, Gill, Barjot, additional, El‐Halabi, Sabine, additional, Chen‐Li, David, additional, Lipsitz, Orly, additional, Rosenblat, Joshua Daniel, additional, Van Rheenen, Tamsyn E., additional, Rodrigues, Nelson B., additional, Mansur, Rodrigo B., additional, Majeed, Amna, additional, Lui, Leanna M. W., additional, Nasri, Flora, additional, Lee, Yena, additional, and Mcintyre, Roger S., additional

Published
2020
Full Text
View/download PDF

49. The emerging role of psilocybin and MDMA in the treatment of mental illness

Author

Gill, Hartej, primary, Gill, Barjot, additional, Chen-Li, David, additional, El-Halabi, Sabine, additional, Rodrigues, Nelson B., additional, Cha, Danielle S., additional, Lipsitz, Orly, additional, Lee, Yena, additional, Rosenblat, Joshua Daniel, additional, Majeed, Amna, additional, Mansur, Rodrigo B., additional, Nasri, Flora, additional, Ho, Roger, additional, and McIntyre, Roger S., additional

Published
2020
Full Text
View/download PDF

50. Synergistic effect of social media use and psychological distress on depression in China during the COVID ‐19 epidemic

Author

Lee, Yena, primary, Yang, Bing Xiang, additional, Liu, Qian, additional, Luo, Dan, additional, Kang, Lijun, additional, Yang, Fang, additional, Ma, Simeng, additional, Lu, Weicong, additional, Chen‐Li, David, additional, Rosenblat, Joshua D., additional, Mansur, Rodrigo B., additional, Nasri, Flora, additional, Subramaniapillai, Mehala, additional, Liu, Zhongchun, additional, McIntyre, Roger S., additional, and Lin, Kangguang, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results